Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
2.575
+0.435 (20.37%)
Dec 19, 2024, 1:19 PM EST - Market open
Silexion Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2013 | FY 2012 |
| Dec '13 Dec 31, 2013 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
| Selling, General & Admin | 0.24 | 0.24 | 0.17 |
| Research & Development | 1.12 | 1.12 | 0.79 |
| Operating Expenses | 1.36 | 1.36 | 0.95 |
| Operating Income | -1.36 | -1.36 | -0.95 |
| Interest Expense | -0 | -0 | -0 |
| Interest & Investment Income | 0 | 0 | 0.01 |
| Currency Exchange Gain (Loss) | 0 | 0 | 0.01 |
| Pretax Income | -1.36 | -1.36 | -0.94 |
| Net Income | -1.36 | -1.36 | -0.94 |
| Net Income to Common | -1.36 | -1.36 | -0.94 |
| Shares Outstanding (Basic) | 0 | 0 | 0 |
| Shares Outstanding (Diluted) | 0 | 0 | 0 |
| Shares Change (YoY) | - | 16.10% | - |
| EPS (Basic) | -81.80 | -81.80 | -65.74 |
| EPS (Diluted) | -81.80 | -81.80 | -65.74 |
| Free Cash Flow | -0.8 | -0.8 | -0.91 |
| Free Cash Flow Per Share | -48.23 | -48.23 | -64.06 |
| EBITDA | -1.36 | -1.36 | -0.95 |
| D&A For EBITDA | 0 | 0 | 0 |
| EBIT | -1.36 | -1.36 | -0.95 |
Source: S&P Capital IQ. Standard template.
Financial Sources.